Press releases
Browse Canadian-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK announces largest private financial contribution to CIHR’s Team Grants initiative addressing threats to Canadian lung health
The $2 million contribution will support the investigation into evidence-based solutions to improve Canadians’ lung health.
-
GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults approved in Canada
Canadians aged 60 years and older can now better protect themselves against RSV disease.
-
GSK completes acquisition of BELLUS Health
GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS.
-
Biopharma company GSK grants $1 million to Halifax-based Canadian Center for Vaccinology (CCfV)
Grant recognizes CCfV’s national leadership and Nova Scotian contribution to Canada’s research capabilities.
-
$3 million joint investment by GSK and U of T to launch the GSK Chair in Vaccine Education and Practice-Oriented Tools
The new chair will aim to close gaps in vaccine education for students and practicing healthcare professionals, with a focus on pharmacists
-
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
Acquisition further strengthens specialty medicines and respiratory pipeline
-
Survey of medical experts reveals opportunities to address organ damage risk with people living with lupus earlier in the course of their disease
Survey of medical experts reveals opportunities to address organ damage risk with people living with lupus.
-
$1.5 million boost to endowed chair from GSK positions U of A to expand leadership in virology research
New investment in long-standing partnership will help create jobs and attract top talent in burgeoning biotech industry, says founding chair
-
GSK Canada submits respiratory syncytial virus (RSV) vaccine candidate for regulatory review
GSK Canada submits respiratory syncytial virus (RSV) vaccine candidate for regulatory review
-
GSK welcomes agreement with the Government of Canada for the provision of pandemic and seasonal influenza vaccines
GSK welcomes agreement with the Government of Canada for the provision of pandemic and seasonal influenza vaccines
-
Regulatory submission for GSK’s daprodustat accepted into Health Canada review
GSK announces that Health Canada has accepted into review the New Drug Submission (NDS) for daprodustat
-
GSK Canada unveils new head office, embracing a hybrid working model centred around individual and collective performance and personal well-being
GSK Canada unveils new head office, embracing a hybrid working model
-
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
-
GSK announces independent Consumer Healthcare company is to be called Haleon
GSK announces independent Consumer Healthcare company is to be called Haleon
-
GSK announces additional purchase agreements with the Government of Canada for COVID-19 monoclonal antibody therapy, Sotrovimab
GSK announces additional purchase agreements with the Government of Canada for COVID-19 monoclonal antibody therapy, Sotrovimab
-
GSK’s JEMPERLI (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer
GSK’s JEMPERLI (dostarlimab for injection) approved in Canada
-
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
-
SHINGRIX approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
SHINGRIX approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
-
For the third consecutive year in a row GSK is named one of Canada’s Top 100 Employers
For the third consecutive year in a row GSK is named one of Canada’s Top 100 Employers
-
NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults
